Intas Pharmaceuticals has scored a major win by signing an exclusive licensing agreement with Shanghai Henlius Biotech. The deal allows Intas to develop and market serplulimab, a groundbreaking antibody, in Europe and India. Serplulimab, also known as Hansizhuang, is a powerful anti-PD-1 monoclonal antibody that has been approved for the treatment of various types of cancer. It has already made waves in China and has received orphan drug designation in the US and Europe. Under the agreement, Henlius will receive a substantial upfront payment of €42m, with the potential for additional milestone payments and royalties. Intas plans to launch serplulimab in India, while its subsidiary Accord Healthcare will handle the European market. This partnership is a game-changer for Intas and positions them as a key player in the global pharmaceutical industry. With serplulimab projected to generate $1.5bn in sales by 2029, the future looks bright for Intas and its groundbreaking antibody.
+ There are no comments
Add yours